

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7





FIGURE 8



2013

2014

2015

2016

2017

2018

2019

2020

2021

FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16






FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20




FIGURE 21




FIGURE 22

a

Drug	IC50 (uM)
REP 2003	4.01
REP 2004	0.065
REP 2006	0.014
REP 2007	0.015
Amprenavir	0.016
Indinavir	0.006
Lopinavir	0.004
Saquinavir	0.003




FIGURE 23




FIGURE 24

Drug	IC50 (uM)		Fold change in IC50
	HIV-1 NL4-3	HIV-1 MRDC4	
REP 2003	4.01	3.69	0.92
REP 2004	0.065	0.046	0.71
REP 2006	0.014	0.014	1.00
REP 2007	0.015	0.013	0.87
Amprenavir	0.017	0.065	3.82
Indinavir	0.006	0.08	13.33
Lopinavir	0.004	0.096	24.00
Saquinavir	0.003	0.006	2.00

FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28








FIGURE 29




FIGURE 30




FIGURE 31




FIGURE 32





FIGURE 33




FIGURE 34




FIGURE 35




FIGURE 36




FIGURE 37

